Insulin resistance in short children with intrauterine growth retardation

P L Hofman1, W S Cutfield, E M Robinson

  • 1Department of Pediatrics, University of Auckland, New Zealand.

Insights

Short children born with intrauterine growth retardation (IUGR) show impaired insulin sensitivity. This early insulin resistance may predict future development of type 2 diabetes and other adult diseases.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Metabolic Research

Background:

  • Intrauterine growth retardation (IUGR) is linked to adult diseases like hypertension and diabetes.
  • Insulin resistance is a common factor in these adult-onset conditions.
  • Early identification of metabolic dysfunction in IUGR children is crucial.

Purpose of the Study:

  • To investigate insulin sensitivity in prepubertal children with IUGR.
  • To compare insulin sensitivity and acute insulin response between IUGR and normal birth weight children.

Main Methods:

  • Compared two groups of short prepubertal children: IUGR (n=15) and normal birth weight (n=12).
  • Utilized a modified frequently sampled intravenous glucose tolerance test.
  • Calculated insulin sensitivity index, acute insulin response, and glucose effectiveness.

Main Results:

  • IUGR children exhibited significantly lower insulin sensitivity (P=0.0048).
  • IUGR subjects showed a higher acute insulin response (P=0.005).
  • No significant difference in glucose effectiveness was observed between groups.

Conclusions:

  • Short prepubertal children with IUGR have impaired insulin sensitivity.
  • This insulin resistance may serve as an early marker for adult-onset diabetes.
  • Early intervention strategies can be developed for at-risk IUGR children.

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.